Clinical Scorecard: Phase 3 Win for TED Therapy
At a Glance
| Category | Detail |
|---|---|
| Condition | Thyroid Eye Disease (TED) |
| Key Mechanisms | Autoimmune condition characterized by orbital inflammation and tissue expansion. |
| Target Population | Patients with moderate-to-severe active thyroid eye disease. |
| Care Setting | Clinical practice, potentially in outpatient settings. |
Key Highlights
- 77% of patients achieved proptosis response at 24 weeks with subcutaneous TEPEZZA.
- Mean proptosis reduction of −3.17 mm at week 24.
- TEPEZZA is the first and only approved therapy for TED.
- Subcutaneous formulation aims to improve convenience without compromising efficacy.
- Safety profile consistent with IV TEPEZZA; common adverse events include muscle spasms and tinnitus.
Guideline-Based Recommendations
Diagnosis
- Diagnosis of TED should consider clinical manifestations such as proptosis and diplopia.
Management
- Subcutaneous TEPEZZA may be considered for patients seeking alternatives to IV therapy.
Monitoring & Follow-up
- Monitor for adverse events, particularly injection site reactions and gastrointestinal symptoms.
Risks
- Potential risks include muscle spasms, tinnitus, weight loss, and ear discomfort.
Patient & Prescribing Data
More than 25,000 patients treated with IV TEPEZZA worldwide.
Subcutaneous delivery may reduce treatment burden and improve accessibility.
Clinical Best Practices
- Consider patient-reported quality of life measures when evaluating treatment outcomes.
- Maintain awareness of the evolving landscape of biologic therapies in TED management.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
